With a multi-disciplinary approach, Fact.MR elaborates an extensive analysis of the historical, current and future outlook of the global benzodiazepine drugs market as well as the factors responsible for such a growth. Our highly dedicated professionals have inputted critical and accurate insights associated with every industry, and region by doing thorough primary and secondary research.

Benzodiazepine drugs are medications which are commonly used to treat lifestyle based ailments such as chronic back pain, insomnia, and anxiety. These are a type of psychoactive drugs, which comprise a fusion of diazepine and benzene rings. Benzodiazepine drugs are widely considered to be short and intermediate term drugs for the treatment of anxiety.

The global benzodiazepine market is expected to witness a sluggish CAGR of 2.7 per cent through the end of the forecast period in 2026. However, while benzodiazepines are expected to witness a demand for high volumes of these drugs, the contribution of such sales will remain moderate in value in terms of market share.

We leverage space-age industrial and digitalization tools to provide avant-garde actionable insights to our clients regarding the benzodiazepine drugs market. For enhancing readers’ experience, the report starts with a basic overview about the benzodiazepine drugs market and its classification. Further, we have considered 2018 as the base year, 2019 as the estimated year, 2019 – 2029 as the stipulated timeframe.

Competitive Assessment

The benzodiazepine drugs market report includes global as well as emerging players:

  • Pfizer Inc.
  • Hoffmann-La Roche Ltd.
  • Bausch Health Companies, Inc.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Lundbeck A/S
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Apotex Inc.
  • Aurobindo Pharma

The insights for each vendor consists of:

  • Company profile
  • SWOT analysis
  • Main market information
  • Market share
  • Revenue, pricing and gross margin

Regional Analysis

Important regions covered in the benzodiazepine drugs market report include:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA

Generic Products to Maintain Rise

North America is set to become the key contributor to the benzodiazepine drugs market, owing to the high rates of consumption for the treatment of anxiety disorders in this region, as anxiety ailments affect around 40 million adults in the United States alone, for every year.

Benzodiazepine drugs are primarily used for anxiety issues, and this accounts for more than 50 per cent of the overall sales figures. This trend is expected to contribute towards increasing adoption rates, even as the consciousness among patients for treatment options increases.

On the other hand, despite the high scope of use, the increasingly strict regulations set by governments with the aim of stopping drug abuse, has restricted benzodiazepine drugs sales as they are limited to retail outlets and pharmacies, with sales only made possible with legal prescriptions. Following North America, the Latin America and Asia Pacific markets are expected to display moderate rates of growth for the foreseeable future.

Further branded medications are continuing to witness diminishing returns owing to the rising popularity of generic variants. The high capital needs for the development of high quality standards for branded drugs, are also bolstering the penetration for generic drugs in the benzodiazepine industry.

The benzodiazepine drugs market report also provides data regarding the key countries in the defined regions.

Segmentation Analysis

By Product:

  • Alprazolam
  • Clonazepam
  • Diazepam
  • Lorazepam

By Application:

  • Anxiety
  • Insomnia
  • Alcohol Withdrawal
  • Seizures

What insights does the benzodiazepine drugs market report provide to the readers?

  • Benzodiazepine drugs market fragmentation on the basis of product type, end use, and region.
  • Comprehensive assessment of upstream starting materials, downstream demand, and present market landscape.
  • Collaborations, R&D projects, acquisitions, and product launches of each benzodiazepine drugs market player.
  • Various regulations imposed by the governments on the consumption of benzodiazepine drugs market in detail.
  • Impact of modern technologies, such as big data & analytics, artificial intelligence, and social media platforms on the global benzodiazepine drugs market.

Deaths and Side Effects from Drug Abuse are Key Restraints for Industry

While benzodiazepine is fairly common drug, an increasing number of factors in recent years have resulted in restricted growth of the market. Some of the major restraints in the industry, is the abuse of these drugs by patients and a number of cases involving overdoses, which have even led to death.

In addition, while short and intermediate terms of consumption of benzodiazepine have been found to be beneficial for patients, long term use can result in a number of side effects, some of which are severe in nature. These can include dizziness, breathing difficulties, tremors, weakness, pneumonia, brain damage, and in extreme cases, even death.

Consequently, a number of governments around the world have set up measures to maintain oversight over relevant prescriptions, which are expected to hamper the growth of the market through the forecast period.

In addition, the number of outpatient visits have increased, which have ultimately led to a prescription of benzodiazepine has shot up. Women are more likely to get the prescriptions for these medications, as this demographic is more likely to be one of the medications to reach into.

Questionnaire answered in the benzodiazepine drugs market report include:

  • How the market for benzodiazepine drugs market has grown over the historic period of 2014-2018?
  • What is the present and future outlook of the global benzodiazepine drugs market on the basis of region?
  • What are the challenges and opportunities for the benzodiazepine drugs market?
  • Why the consumption of benzodiazepine drugs market highest in region?
  • In which year segment is expected to overtake segment?


Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai, United Arab Emirates
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog – https://blog.factmr.com/